|
1
|
Baecker A, Liu X, La Vecchia C and Zhang
ZF: Worldwide incidence of hepatocellular carcinoma cases
attributable to major risk factors. Eur J Cancer Prev. 27:205–212.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu
J, Dai Y, Xie Y, Lin H, Liang X and Cai X: Phosphorylated ERK is a
potential prognostic biomarker for Sorafenib response in
hepatocellular carcinoma. Cancer Med. 6:2787–2795. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kudo M: Systemic Therapy for
hepatocellular carcinoma: 2017 Update. Oncology. 93 (Suppl
1):S135–S146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kudo M: Immuno-oncology in hepatocellular
carcinoma: 2017 Update. Oncology. 93 (Suppl 1):S147–S159.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Farinati F, Marino D, De Giorgio M, Baldan
A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA,
Benvegnù L, et al: Diagnostic and prognostic role of
alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am
J Gastroenterol. 101:524–532. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nishimoto S, Fukuda D, Higashikuni Y,
Tanaka K, Hirata Y, Murata C, Kim-Kaneyama JR, Sato F, Bando M,
Yagi S, et al: Obesity-induced DNA released from adipocytes
stimulates chronic adipose tissue inflammation and insulin
resistance. Sci Adv. 2(e1501332)2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH,
Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ and Chen CJ: Hepatitis C
virus seromarkers and subsequent risk of hepatocellular carcinoma:
Long-term predictors from a community-based cohort study. J Clin
Oncol. 28:4587–4593. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jee SH, Ohrr H, Sull JW and Samet JM:
Cigarette smoking, alcohol drinking, hepatitis B, and risk for
hepatocellular carcinoma in Korea. J Natl Cancer Inst.
96:1851–1856. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kannangai R, Wang J, Liu QZ, Sahin F and
Torbenson M: Survivin-1 overexpression in hepatocellular carcinoma
is associated with p53 dysregulation. Int J Gastrointest Cancer.
35:53–60. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jin B, Wang X, Jin Y, Xia W, Chen B, Liu
L, Chen Z, Hong L, Du W, Yan K, et al: Detection of serum gastric
cancer-associated MG7-Ag from gastric cancer patients using a
sensitive and convenient ELISA method. Cancer Invest. 27:227–233.
2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chauhan SC, Vinayek N, Maher DM, Bell MC,
Dunham KA, Koch MD, Lio Y and Jaggi M: Combined staining of TAG-72,
MUC1, and CA125 improves labeling sensitivity in ovarian cancer:
Antigens for multi-targeted antibody-guided therapy. J Histochem
Cytochem. 55:867–875. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xue F, Higgs BW, Huang J, Morehouse C, Zhu
W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, et al: HERC5 is a
prognostic biomarker for post-liver transplant recurrent human
hepatocellular carcinoma. J Transl Med. 13(379)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bernassola F, Karin M, Ciechanover A and
Melino G: The HECT family of E3 ubiquitin ligases: Multiple players
in cancer development. Cancer Cell. 14:10–21. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Torbenson MS, Ng IOL, Park YN, Roncalli M
and Sakamoto M: Hepatocellular Carcinoma. In: WHO Classification of
Tumours Editorial Board. Digestive system tumours. 5th edition.
International Agency for Research on Cancer, Lyon, pp229-239,
2019.
|
|
16
|
Ramos-Vara JA and Miller MA: When tissue
antigens and antibodies get along: Revisiting the technical aspects
of immunohistochemistry-the red, brown, and blue technique. Vet
Pathol. 51:42–87. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Torlakovic EE, Cheung CC, D'Arrigo C,
Dietel M, Francis GD, Gilks CB, Hall JA, Hornick JL, Ibrahim M,
Marchetti A, et al: Evolution of quality assurance for clinical
immunohistochemistry in the era of precision medicine-part 2:
Immunohistochemistry test performance characteristics. Appl
Immunohistochem Mol Morphol. 25:79–85. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bolocan A, Păduraru DN, Nițipir C,
Hainăroșie R, Pițuru SM, Diaconu C, Suceveanu A and Stoian CD:
Mixed adenoneuroendocrine carcinoma of the gastrointestinal
tract-features, diagnosis, management and prognosis. Rom Biotechnol
Lett. 23:14193–14202. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gurtsevitch VE: Human oncogenic viruses:
Hepatitis B and hepatitis C viruses and their role in
hepatocarcinogenesis. Biochemistry (Mosc). 73:504–513.
2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Donato F, Tagger A, Gelatti U, Parrinello
G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML,
Martelli C, et al: Alcohol and hepatocellular carcinoma: The effect
of lifetime intake and hepatitis virus infections in men and women.
Am J Epidemiol. 155:323–331. 2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ferenci P, Fried M, Labrecque D, Bruix J,
Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA,
et al: World gastroenterology organisation guideline.
Hepatocellular carcinoma (HCC): A global perspective. J
Gastrointestin Liver Dis. 19:311–317. 2010.PubMed/NCBI
|
|
22
|
Suceveanu AI, Pantea Stoian A, Mazilu L,
Voinea F, Hainăroșie R, Diaconu CC, Pițuru S, Nițipir C, Badiu DC,
Ceaușu I and Suceveanu AP: Interferon-free therapy is not a trigger
for hepatocellular carcinoma in patients with chronic infection
with hepatitis C virus. Farmacia. 66:904–908. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Carr BI, Akkiz H, Üsküdar O, Yalçın K,
Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A,
Tokmak S, et al: HCC with low- and normal-serum alpha-fetoprotein
levels. Clin Pract (Lond). 15:453–464. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yang SL, Liu LP, Yang S, Liu L, Ren JW,
Fang X, Chen GG and Lai PB: Preoperative serum α-fetoprotein and
prognosis after hepatectomy for hepatocellular carcinoma. Br J
Surg. 103:716–724. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
An SL, Xiao T, Wang LM, Rong WQ, Wu F,
Feng L, Liu FQ, Tian F and Wu JX: Prognostic significance of
preoperative serum alpha-fetoprotein in hepatocellular carcinoma
and correlation with clinicopathological factors: A single-center
experience from China. Asian Pac J Cancer Prev. 16:4421–4427.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Omata M, Cheng AL, Kokudo N, Kudo M, Lee
JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al:
Asia-Pacific clinical practice guidelines on the management of
hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ardeleanu V, Georgescu C, Frîncu LD,
Frâncu LL and Vesa D: Angiogenesis as prospective molecular biology
technique for cancer study. Rom Biotehnol Lett. 19:9637–9648.
2014.
|
|
28
|
Ardeleanu V, Francu L and Georgescu C:
Neoangiogenesis. Assessment in esophageal adenocarcinomas. Indian J
Surg. 77 (Suppl 3):S971–S976. 2015.PubMed/NCBI View Article : Google Scholar
|
